Results 11 to 20 of about 8,116 (132)

Varenicline Prevents LPS-Induced Inflammatory Response via Nicotinic Acetylcholine Receptors in RAW 264.7 Macrophages

Frontiers in Molecular Biosciences, 2021
The cholinergic anti-inflammatory pathway plays an important role in controlling inflammation. This study investigated the effects of varenicline, an α7 nicotinic acetylcholine receptor (α7nAChR) agonist, on inflammatory cytokine levels, cell ...
Elif Baris, Elif Baris, Hande Efe, Mukaddes Gumustekin, Mualla Aylin Arici, Metiner Tosun   +5 more
doaj   +1 more source

Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting

BMJ Open, 2021
Objectives To evaluate the real-world association between varenicline and neuropsychiatric adverse events (NPAEs) in general and chronic obstructive pulmonary disease (COPD) population with and without psychiatric disorders compared with nicotine ...
Yuanyuan Wang, Bob Wilffert, Eelko Hak, H. Marike Boezen, Jens H. Bos, Catharina C.M. Schuiling-Veninga, Job F. M. van Boven   +6 more
doaj   +1 more source

A case report on varenicline induced delirium in an alcohol and nicotine dependent patient

Indian Journal of Psychological Medicine, 2015
Varenicline is a smoking cessation agent. Varenicline acts as a partial agonist of α4β2 neuronal nicotinic acetylcholine receptor and prevents nicotine binding to the same.
A Lakshmi Narayan, H S Virupaksha, G Thejaswi, G R Saraswathy, V Madhavan, Murali Thyloth   +5 more
doaj   +1 more source

Varenicline and Risk of Self-Harm: A Nested Case-Control Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates.
Mina Tadrous, Diana Martins, Zhan Yao, Muhammad M Mamdani, David N Juurlink, Tara Gomes, Tony Antoniou   +6 more
doaj   +1 more source

Adverse Neuropsychiatric Events Associated with Varenicline: A Case Series

Psychiatry and Behavioral Sciences, 2021
Varenicline is an orally administered α4β2 nicotinic acetylcholine (Ach) receptor, partial agonist. This drug has been known to be more effective in the treatment of nicotine withdrawal than bupropion and nicotine replacement therapies ...
Burak Erman Menku, Taylan Altiparmak, Bahadir Genis, Behcet Cosar   +3 more
doaj   +1 more source

Use of varenicline and nicotine replacement therapy in people with and without general practitioner-recorded dementia: retrospective cohort study of routine electronic medical records

BMJ Open, 2019
Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor, Tim Jones, Taha Itani, Richard Martin, Gemma Taylor, Kyla Thomas, Neil Davies   +6 more
doaj   +1 more source

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]

PLoS ONE, 2016
UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith, Revital Amiaz, Tian-Mei Si, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Yanhong Liu, Mary Youseff, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M Davis   +14 more
doaj   +1 more source

Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

Journal of Pharmacological Sciences, 2018
Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled
Mitsuhisa Koga, Yuki Kanaoka, Tetsushi Tashiro, Nagisa Hashidume, Yasufumi Kataoka, Atsushi Yamauchi   +5 more
doaj   +1 more source

Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trialResearch in context

The Lancet Regional Health. Europe
Summary: Background: Alcohol use disorder (AUD) is associated with an enormous burden of disease and cost to society. The dopamine deficiency hypothesis posits that negative reinforcement generated by a low brain dopamine state drives ethanol intake ...
Bo Söderpalm, Helga Lidö, Johan Franck, Anders Håkansson, Daniel Lindqvist, Markus Heilig, Joar Guterstam, Markus Samuelson, Barbro Askerup, Cecilia Wallmark-Nilsson, Andrea de Bejczy   +10 more
doaj   +1 more source

Characteristics of first-time varenicline users – A cross-sectional study in Finnish quitters

BMC Public Health, 2017
Background Varenicline is an efficacious medicine for smoking cessation (SC) but little is known about the characteristics of varenicline users. This study examined the characteristics of first-time (naïve) varenicline users in Finland and compared those
Hanna E. Tervonen, Juha H. O. Turunen, Christine L. Baker, Juha Laine, Kari Linden   +4 more
doaj   +1 more source